Search

How to apply for an EHA Kick-off Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Kick-off Grant application.

The invisible burden of the pandemic

Apr 06 2022

Writing about my perspective on the COVID-19 pandemic has been on my mind for some time.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Presentations

EHA-ISHBT Hematology Tutorial

Session 1: Congenital and acquired neutropenias and bone marrow failure

Lecture: F Fioredda (here)
Clinical case: F Fioredda (here)
Self-assessment cases:
Speaker 1: M Mahapatra (Permission not granted)
Speaker 2: A Khurana (here)
Session 2: Hemolytic Anemia

Lecture: L Da Costa (Not available)
Clinical case: L…

Publications

Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, Klamroth R, Lassila R, Leebeek FWG, Makris M, Owaidah T, Sholzberg M, Tiede A, Werring DJ, van der Worp HB,…

Senior Financial Controller

Hematologic diseases afflict millions of Europeans each year.

The Clot Thickens

Jun 11 2016 Posted in Press releases

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).